 |
| Reference |
|
-
Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non–Q‑wave myocardial infarction.
N Engl J Med 1998;338:1488–1497.
|
|
|
|
|
|
|
|
|
|
|
|
| AGGRASTAT is a registered trademark of Merck & Co., Inc., Whitehouse Station, NJ, USA
|
|
|
|
|
|
